Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Assertio Holdings, Inc. (Nasdaq: ASRT) reported a 32% increase in net product sales year-over-year for Q3 2022, totaling $34.3 million. Adjusted EBITDA rose 36% to $21.4 million. The company refinanced its debt to lower costs and extend maturity, enhancing financial flexibility. Assertio expects Sympazan to contribute an additional $1 million in sales in Q4. With cash reserves at $64.8 million, the company revised its full-year guidance to anticipate net product sales exceeding $141 million and adjusted EBITDA surpassing $86 million, reflecting positive operational performance.
Assertio Holdings, Inc. (Nasdaq: ASRT) will release its third-quarter 2022 financial results on November 8, 2022, after market close. A live webcast of the earnings call will follow at 4:30 p.m. ET. Investors can access the call via Assertio's investor relations website. The company focuses on specialty pharmaceuticals, utilizing a non-personal promotional model to enhance product differentiation. Assertio emphasizes growth opportunities through integrating new assets and business development initiatives.
Assertio Holdings has acquired an exclusive license for Sympazan (clobazam) oral film from Aquestive Therapeutics for $9.0 million upfront and an additional $6.0 million upon patent allowance, expected in 2023. This transaction aims to enhance Assertio's portfolio and extend patent coverage potentially to 2039. Sympazan, designed for LGS patients, is anticipated to contribute $4.0 - $4.5 million in adjusted EBITDA and $0.05 in adjusted EPS, aligning with Assertio's growth strategy to achieve $40 million in gross profit by 2024.
Assertio Holdings (Nasdaq: ASRT), a specialty pharmaceutical company, announced its participation in investor conferences during October 2022. Key events include the Windy City Roundup 2022 on October 13, 2022, at Swissotel, Chicago, and the LD Micro Main Event XV on October 25, 2022, at Luxe Sunset Boulevard Hotel, Los Angeles. Presentations will occur at 11:00 a.m. CT and 10:30 a.m. PT, respectively. Management will also host one-on-one meetings. For further details, interested parties should contact Investor Relations.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced that CEO Dan Peisert will participate in investor meetings on September 14, 2022, at the Lake Street Capital Markets Best Ideas Growth Conference (BIG6) in New York City. The event will include one-on-one meetings with management, providing an opportunity for investors to engage directly. Assertio specializes in differentiated pharmaceutical products across neurology, hospital, and pain/inflammation sectors and has grown through strategic business initiatives.
Assertio Holdings has successfully closed a $70 million offering of 6.50% convertible senior notes due 2027, including a full exercise of an option for an additional $10 million. The net proceeds of approximately $65.9 million will be used to repurchase existing debt and for general corporate purposes. The notes will accrue interest, payable semi-annually, and can be converted into cash or common stock at Assertio's discretion, with an initial conversion price of about $4.09 per share. The company prohibits incurring additional liens without securing the notes equally.
Assertio Holdings, Inc. (Nasdaq: ASRT) has priced a $60 million offering of 6.50% convertible senior notes due 2027, scheduled to settle on August 25, 2022. The company expects net proceeds of approximately $56.7 million, intended for repurchasing senior secured notes and general corporate purposes. The initial conversion rate is 244.2003 shares per $1,000 note, with a conversion price of $4.09, representing a 12.50% premium over the last stock price. The notes may be redeemed after September 8, 2025, under specific stock price conditions.
Assertio Holdings, Inc. (Nasdaq: ASRT) has announced its plan to offer $60 million in convertible senior notes due 2027, with the option for an additional $10 million. The notes, which will be senior and unsecured, will accrue semi-annual interest and can be converted into cash, shares, or a mix thereof. Proceeds are intended for repurchasing senior secured notes maturing in January 2024 and for general corporate purposes. The offering is a private placement, not registered under the Securities Act.
Assertio Holdings (ASRT) plans to disclose its second quarter 2022 financial results on August 8, 2022, prior to market opening. The management will host a live conference call at 11:30 a.m. ET to discuss the results. Interested parties can access the webcast via the company's investor relations website and should connect 10 minutes early to allow time for any necessary software downloads. A replay of the call will be available shortly after its conclusion.
Assertio specializes in differentiated pharmaceutical products, aiming to enhance its commercial portfolio through strategic opportunities.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced on July 12, 2022, that it granted new employees a total of 17,772 restricted stock units (RSUs) and 18,553 stock options effective July 1, 2022. This incentive aligns with NASDAQ Listing Rule 5635(c)(4) and is contingent on the employees' continued service. The options have an exercise price of $3.15 per share, matching the company's stock closing price on the grant date, with vesting scheduled over three years.